Disease Overview：Retinal Vein Occlusion（RVO）
Retinal vein occlusion (RVO) is a common retinal vascular disorder characterized by partial or complete blockage of the central or branch retinal vein, leading to impaired venous outflow, retinal hemorrhages, macular edema, and potential vision loss. It predominantly affects individuals over 50 years old and is associated with systemic risk factors including hypertension, diabetes mellitus, hyperlipidemia, glaucoma, and hypercoagulable states. Clinical presentation ranges from asymptomatic findings on routine exam to sudden, painless, unilateral visual decline. Optical coherence tomography (OCT) and fluorescein angiography are key diagnostic tools for assessing macular involvement and ischemia. Management focuses on addressing underlying comorbidities and mitigating complications—particularly macular edema—through intravitreal anti-VEGF agents (e.g., ranibizumab, aflibercept), corticosteroid implants, or laser photocoagulation in ischemic cases. Timely intervention significantly improves visual prognosis, though chronic RVO may lead to neovascular glaucoma or irreversible atrophy.
China offers compelling advantages for RVO treatment: its ophthalmology centers—especially tier-3 hospitals in Beijing, Shanghai, and Guangzhou—boast internationally trained retinal specialists with extensive experience in complex vascular cases. State-of-the-art OCT-angiography systems, widefield imaging platforms, and real-time intraoperative navigation enhance diagnostic precision and therapeutic accuracy. Over 12,000 documented RVO interventions annually demonstrate consistent functional outcomes, with >75% of patients achieving ≥15-letter improvement in best-corrected visual acuity after three anti-VEGF injections. Treatment costs in China average 40–60% lower than in the US or Western Europe, without compromising clinical standards or regulatory oversight. As a dedicated medical tourism agency, we facilitate seamless access for international patients—handling hospital referrals, coordinating multidisciplinary evaluations, providing itemized, transparent pricing in advance, arranging interpreters and accommodation, and offering post-treatment follow-up support—all tailored to individual clinical needs and travel logistics.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Retinal Vein Occlusion
Non-Surgical / Conservative Management
*Target criteria:* Mild non-ischemic RVO, stable vision, no macular edema or neovascularization.
- •Baseline diagnostics (mandatory):
- Fundus fluorescein angiography (FFA): $65–$89 - Visual field testing + intraocular pressure: $28–$37
- •Pharmacotherapy (3–6 months):
- Intravitreal dexamethasone implant (0.7 mg): $295–$340 per implant (1–2 implants/year) - Oral anticoagulant (warfarin, monitored): $12–$18/month (INR testing included)
- •Systemic control (required):
Surgical / Procedural Interventions
*Eligibility:* Ischemic RVO, persistent macular edema >3 months, or anterior segment neovascularization.
- •Preoperative workup:
- Coagulation panel + homocysteine: $48–$62
- •Procedures:
- Vitrectomy with internal limiting membrane peeling + adjunctive anti-VEGF: $1,420–$1,780 (single-stage, includes anesthesia, disposables, 1-day admission) - Pars plana vitrectomy + endolaser for neovascular glaucoma: $1,850–$2,240
Special / Complex Condition Management
- •RVO with neovascular glaucoma (NVG):
- •Recurrent edema refractory to 6 anti-VEGF injections:
- •Young patients (<45 years) with thrombophilia workup:
Quick Selection Guide
- •Age <50, budget-constrained, mild edema: Start with OCT + FFA ($107–$147), then oral anticoagulation + monthly monitoring ($12–$18/month). Total Year 1: ~$220–$310.
- •Age 50–75, moderate-severe edema, comorbid HTN/DM: Anti-VEGF monotherapy (4 injections × $350 avg = $1,400) + systemic control ($35–$48). Total Year 1: $1,450–$1,520.
- •Age >75, ischemic RVO + NVG: Immediate PRP ($210) + trabeculectomy + bevacizumab ($2,380). Total: $2,590–$2,670.
- •High-risk comorbidities (CKD, AFib): Prioritize systemic anticoagulation + dexamethasone implant ($315) over repeated anti-VEGF. Year 1 cost: $420–$510.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Retinal Vein Occlusion Medical Vacation Packages
Curated transparent all-inclusive packages combining Retinal Vein Occlusion treatment with China top medical destinations:
